-
2023-507660-39-00
5
2024-12-03
Myotonic dystrophy type 1 (DM1)
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2023-503316-33-00
5
2024-09-26
patients with a positive status for molecular residual disease (MRD) [
-
2023-507353-15-00
5
2024-09-10
idiopathic pulmonary fibrosis (IPF)
-
2023-509042-35-01
4
2024-07-18
Adults patients will be included in the hematology departments. Eligib
-
2022-500013-32-01
5
2024-07-05
Adrenocortical carcinoma
-
2024-512004-19-01
5
2024-07-02
Head trauma
-
2024-514587-44-00
4
2024-06-17
Aortic stenosis
-
2023-506590-35-00
4
2024-06-13
Large-Cell NeuroEndocrine
Carcinoma of the lung
-
2023-504486-23-00
5
2024-05-29
Venous thromboembolism
-
2023-503645-63-00
5
2024-04-25
Patients aged 65 years or older, hospitalized in a non-ICU ward for a
-
2023-508531-30-00
4
2024-03-25
grade 1 glioma/mixed glio-neuronal tumors or pleomorphic xanthoastrocy
-
2022-500862-93-00
5
2024-02-01
Pulmonary Hypertension
-
2023-504555-27-00
5
2023-11-28
Myelodysplastic syndrome (MDS)
-
2023-504644-34-00
5
2023-11-08
Subject with chronic coccygodynia
-
2022-502007-30-00
5
2023-11-07
Kidney transplant
-
2022-500974-33-00
5
2023-08-12
acute venous thromboembolism event
-
2022-501494-39-00
5
2023-03-28
Uncontrolled Hypertension IN patients with moderate to severe chronic
-
2023-503481-23-00
5
2023-03-20
Maintenance treatment in metastatic non-squamous lung cancer
-
2022-500234-29-00
5
2022-11-28
Rheumatoid Arthritis
-
2024-511005-39-00
10
2022-06-22
Raynaud phenomenon
-
2023-506990-37-00
5
2021-07-13
Alcohol addiction
-
2023-505187-11-00
7
2021-03-01
Duchenne Muscular Dystrophy
-
2024-514542-37-00
9
2020-08-13
Select advanced solid tumors and Non-Small Cell Lung Cancer with MET a